Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of elecoglipron compared with placebo in adults with Type 2 Diabetes Mellitus T2DM who are already being treated with insulin and other glucose-lowering medications. This Phase III study focuses on adults with T2DM who have had the condition for at least 90 days and meet certain health criteria. Participants will be randomly assigned to one of three groups elecoglipron at dose level 1, elecoglipron at dose level 2, or placebo. All treatments are taken orally once daily. The study treatment period lasts up to 40 weeks, during which participants continue their background insulin and glucose-lowering medications. During the study, participants will have regular assessments to monitor changes in blood sugar control, including Hemoglobin A1c HbA1c, body weight, blood pressure, and insulin dose. Researchers will also track safety, side effects, and tolerability. The main outcome is the change in HbA1c from baseline to Week 40. Overall, participation involves visits for monitoring and evaluations over approximately 40 weeks.
Actively Recruiting
Researchers are evaluating the effectiveness, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with type 2 diabetes mellitus T2DM who have an increased cardiovascular risk. This study focuses on patients whose diabetes is not adequately controlled with lifestyle changes or stable glucose-lowering medications. The trial is a Phase III, randomized, open-label, parallel-group study sponsored by AstraZeneca. Participants will be randomly assigned to receive either elecoglipron or semaglutide, both administered orally once daily at specified doses. The treatment period lasts up to 52 weeks, during which the effects of these medications on blood sugar control and other health measures will be assessed. Throughout the study, participants will undergo regular evaluations including measurements of hemoglobin A1c HbA1c, body weight, and blood pressure at baseline and at 52 weeks. Researchers will monitor changes in these parameters to assess the impact of the treatments. Safety and tolerability will also be closely followed during the trial period.
Actively Recruiting
Researchers are evaluating a drug called BNT3214 also known as PM8102 in adults with advanced solid tumors to assess its safety and how well it works. This early-phase trial includes three parts the first two are dose-finding phases to identify the safest and most effective dose, while the third part tests selected doses across various cancer types. The study aims to understand the drugs effects in patients with tumors that have not responded to standard treatments or for whom standard options are unsuitable. Participants will receive BNT3214 through intravenous infusion. In Parts A and B, different dose levels will be tested, with Part B being optional depending on initial safety results. Part C will use doses selected based on earlier findings and includes both dose optimization and dose expansion groups. Treatment can continue for up to two years or until disease progression, unacceptable side effects, or other reasons for stopping treatment occur. During the study, participants will have regular assessments including monitoring for side effects, blood tests to measure how the drug behaves in the body, and evaluations of tumor response using standard criteria. Safety will be closely watched throughout treatment and for 90 days after the last dose. The main outcomes measured include treatment-related adverse events and tumor response rates, with follow-up lasting up to 30 months to track disease control and duration of response.
Actively Recruiting
Researchers are evaluating the effects of MAR001 compared to a placebo in adults with elevated triglycerides TG and remnant cholesterol RC. This Phase 2b, randomized, double-blind, placebo-controlled study aims to understand how MAR001 impacts TG levels in people with specific cholesterol conditions. The study includes two parts, focusing on different ranges of baseline triglyceride levels to assess the treatments effects. Participants in Part A with TG levels between 150 and 880 mgdL will receive one of three doses of MAR001 or placebo by subcutaneous injection every four weeks. In Part B, participants with higher TG levels between 450 and 2000 mgdL will receive a dose chosen based on Part A results, also by subcutaneous injection every four weeks. The study consists of a screening period lasting up to 8 weeks, a 24-week treatment phase, and a 12-week safety follow-up with two clinic visits. During the trial, participants will undergo assessments including clinical visits at specified weeks, laboratory tests, and monitoring for safety and treatment effects. Researchers will measure changes in triglyceride levels primarily at 12 weeks, along with secondary outcomes at various time points. The total participation duration includes screening, treatment, and follow-up periods, allowing for comprehensive evaluation of MAR001s impact and safety in this population.